для лечения пациентов с метастатическим немелкоклеточным раком легкого с экспрессией киназы анапластической лимфомы (ALK), ранее получавших кризотиниб и не ответивших на лечение.

CERITINIB

ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non- small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.